Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes (FTSG)
Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes: A Randomized, Controlled Trial
Sponsor: Brigham and Women's Hospital
Terminated
Due to the insufficient accrual rate and strategic reasons to focus our efforts on higher impact research projects.
Other terminated trials from Brigham and Women's Hospital
A PHASE2/PHASE3 clinical study on Full Thickness Skin Graft Healing and Surgical Wound, this trial is terminated or withdrawn. The trial is conducted by Brigham and Women's Hospital and has accumulated 7 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2019 — Dec 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .